DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20202374

Depot medroxyprogesterone: the way forward

Sumita Mehta, Ekta Kale, Fatima Rashid

Abstract


India has a high rate of unintended pregnancies and abortions contribute to 8% of maternal mortality. The addition of injection depot medroxyprogesterone (DMPA) to the basket of contraceptives has allowed women to use a long-term contraceptive which does not require any user action to maintain efficacy and whose effect is easily reversible. Injectable progestins are now estimated to be used by 6% women globally.


Keywords


Contraception, Depot medroxy progesterone, Injectable contraceptive

Full Text:

PDF

References


Jacobstein R, Polis CB. Progestin-only contraception: injectables and implants. Best Pract Res Clin Obstet Gynaecol. 2014;28(6):795-806.

Dianat S, Fox E, Ahrens KA, Upadhyay UD, Zlidar VM, Gallo MF, et al. Side effects and health benefits of depot medroxyprogesterone acetate: a systematic review. Obstet Gynecol. 2019;133(2):332-41.

Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, et al. Depo provera: position paper on clinical use, effectiveness and side effects. Br J Fam Plann. 2000;26(1):52-3.

Lopez LM, Ramesh S, Chen M, Edelman A, Otterness C, Trussell J, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2016;(8):CD008815.